The founders of European start-ups HemoCORM Ltd. and Alfama Inc. are hoping to harness potentially therapeutic effects of carbon monoxide (CO) through developing a range of CO releasing molecules that deliver the molecule into the body under certain conditions.
CO is produced naturally in the body as a result of the breakdown of heme oxygenase, an enzyme involved in the recycling of iron. But CO is more than simply...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?